Cue Biopharma, Inc.
CUE
$0.56
-$0.01-1.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.68M | -38.90M | -40.58M | -40.67M | -44.61M |
| Total Depreciation and Amortization | 2.33M | 2.32M | 2.35M | 2.35M | 3.29M |
| Total Amortization of Deferred Charges | 37.00K | 37.00K | 37.00K | 37.00K | 37.00K |
| Total Other Non-Cash Items | 5.40M | 5.78M | 6.31M | 6.88M | 7.70M |
| Change in Net Operating Assets | 272.00K | 2.62M | -2.83M | -4.93M | -4.67M |
| Cash from Operations | -29.64M | -28.14M | -34.72M | -36.33M | -38.26M |
| Capital Expenditure | -179.00K | -178.00K | -161.00K | -66.00K | -64.00K |
| Sale of Property, Plant, and Equipment | 21.00K | 98.00K | 98.00K | 98.00K | 97.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.79M | -- | -- | -- | 0.00 |
| Cash from Investing | -6.95M | -80.00K | -63.00K | 32.00K | 33.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.00M | -4.00M | -4.00M | -4.00M | -4.00M |
| Issuance of Common Stock | 19.87M | 29.69M | 10.89M | 14.24M | 19.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15.87M | 25.69M | 6.89M | 10.24M | 15.96M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.72M | -2.54M | -27.89M | -26.05M | -22.27M |